Gene · 5685
PSMA4: proteasome 20S subunit alpha 4
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMA4: proteasome 20S subunit alpha 4. Genes, record 5685. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5685
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P25789 | Proteasome subunit alpha type-4 | 261 | 177 | Ensembl, GeneID, HGNC |
Source UniProt
Patents41
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59507 | P25789 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 59509 | P25789 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 77 | P25789 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 77 | P25789 | Espacenet |
| WO 2024240908 A1 | 2024-11-28 | 27 | P25789 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67863 | P25789 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67875 | P25789 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170834 | P25789 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170846 | P25789 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9059 | P25789 | Espacenet |
1 to 10 of 41
See all 41 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants902
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMA4 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 7 | 2025 |
| U10AA008401 | Collaborative Study on the Genetics of Alcoholism (COGA). | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 4 | 2025 |
| R35CA197449 | Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer Research | 3 | 2025 |
| ZIAAI000904 | Staphylococcal pathogenesis | 3 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016520 | Abramson Cancer Center Support Grant | 2 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 902Source NIH's project files
See all 902 nih grantsPapers825
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multi-Omics Genome-Wide to Explore the Formation and Development Targets for Intracranial Aneurysms. | FASEB J | 2026 | 42698337 | PubTator, text mining | PubMed |
| From locus to gene: causal inference and experimental validation prioritize PSMA4 as a candidate target in lung adenocarcinoma. | Am J Cancer Res | 2026 | 42163891 | PubTator, text mining | PubMed |
| Identification of PSMA4 as a Therapeutic Target for Atherosclerosis: A Comprehensive Multiomics Mendelian Randomization Analysis. | Ann Hum Genet | 2026 | 42032825 | PubTator, text mining | PubMed |
| A comparative analysis of serum and tissue proteomic profiles in non-small cell lung cancer patients with or without brain metastasis. | Cell Death Discov | 2026 | 41974650 | PubTator, text mining | PubMed |
| Integrating genome-wide association studies with quantitative trait loci prioritised PSMA4 as a risk gene for pneumonia. | ERJ Open Res | 2026 | 41953759 | PubTator, text mining | PubMed |
| Exploring the shared genetic architecture between periodontitis and cardiovascular disease. | BDJ Open | 2026 | 41916952 | PubTator, text mining | PubMed |
| Machine learning and single-cell RNA sequencing analyses identify MS-related monocytes and a five-gene candidate biomarker signature. | Front Neurol | 2026 | 41756175 | PubTator, text mining | PubMed |
| Proteomic Insights into Venous Thromboembolism. | Med Sci (Basel) | 2026 | 41718141 | PubTator, text mining | PubMed |
| PSMA4 as a Druggable Target in Hidradenitis Suppurativa: Evidence From Mendelian Randomization and Single-Cell Transcriptomics. | Mediators Inflamm | 2026 | 41685341 | PubTator, text mining | PubMed |
| Identifying Therapeutic Targets for Bronchial Asthma: Systematic Druggable Genome-Wide Mendelian Randomization. | Health Sci Rep | 2026 | 41573111 | PubTator, text mining | PubMed |
1 to 10 of 825
See all 825 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5685
GET https://conductscience.org/api/genes/v1/5685/patents?page=2